Rystiggo MG denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rystiggo (rozanolixizumab-noli) as Experimental — and Why You Can Appeal

Cigna occasionally denies Rystiggo for generalized myasthenia gravis (gMG) by classifying it as experimental or investigational, typically by citing limited long-term safety data, absence from the plan's approved technology list, or application outside the FDA-approved patient population. This rationale is frequently unsupportable: Rystiggo received full FDA approval for adults with gMG who are anti-AChR or anti-MuSK antibody positive, and FDA approval is the primary threshold for distinguishing approved from experimental treatments. A denial of an FDA-approved drug as "experimental" is one of the strongest categories for appeal reversal.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered plans must allow independent external review by a nationally accredited independent review organization (IRO). ERISA Section 503 requires a full-and-fair internal review with specific written reasons citing plan provisions. If your gMG is severe, unstable, or in exacerbation, expedited review compresses the standard timeline significantly and should be requested explicitly. The external review window is generally available for roughly four months after internal remedies are exhausted.

## The Appeal Process and Timeline

1. Request the denial letter in writing — it must cite the specific plan provision or coverage policy used to classify Rystiggo as experimental. 2. File a first-level internal appeal, attaching FDA approval documentation and the prescribing label. 3. If the internal appeal is denied, request external review immediately. External reviewers applying standard medical evidence criteria routinely reverse "experimental" denials for FDA-approved drugs used within their labeled indication. 4. File a complaint with your state insurance commissioner in parallel if Cigna fails to process the appeal within required timeframes.

## Documentation to Gather

• FDA approval documentation: the FDA's approval letter or product page for Rystiggo confirming its approved indication for gMG in antibody-positive adults. This is the single most important document for refuting an experimental denial.
• Prescribing information (label): the FDA-approved prescribing label — confirm the patient's diagnosis, antibody status, and clinical situation fall within the labeled indication.
• Diagnosis and antibody status confirmation: records confirming gMG diagnosis and anti-AChR or anti-MuSK antibody positivity.
• Prior treatment history: documentation of prior gMG treatments tried and outcomes, demonstrating treatment-refractory or inadequately controlled disease.
• Neurologist medical-necessity letter: a letter from the treating neurologist confirming the patient meets the FDA-labeled indication and explaining the clinical rationale for Rystiggo over alternatives already tried.
• Applicable guideline reference: a citation to the relevant neurology society guidance (such as the applicable AAN or Myasthenia Gravis Foundation of America guideline) that addresses biologic therapies in refractory gMG.

## Criteria-Mapping Structure

Obtain Cigna's published coverage policy for Rystiggo or for FcRn inhibitors in gMG. For each condition listed in the policy, provide the specific chart fact or document satisfying it. Explicitly state that FDA approval categorically removes a drug from "experimental" status under the standard definition used by accredited IROs, and that any policy provision labeling an FDA-approved drug experimental must be interpreted consistently with that standard.